focus -WSS

focus

author：focus 2025-09-10 08:41:14 - browse：3562

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： New oral drug delivery patch is modeled after octopus tentacles

hotspot

knowledge

WSS

What Congress can do to address the rural doctor shortage

Second xenotransplant done with gene

Why are Kaiser Permanente staff considering a strike?

Changes to biosimilar regulatory framework must prioritize patients

Medicare innovation center doesn’t save money, experts say

The stability of $0 premiums in Medicare Advantage

focus

focus

explore

Jerome Adams on the need for new antivirals for Covid

Setback for rare diseases as Taysha Gene Therapies pulls back

United colonoscopy coverage change 'may cost lives,' doctors say

Nobel honors Karikó and Weissman's enduring partnership

Drug repurposing or repositioning? The language matters

Drug for rare kidney disease narrowly misses mark in clinical trial

ChatGPT in medicine: STAT answers readers' burning questions

The stability of $0 premiums in Medicare Advantage

Medical leaders decry Supreme Court decision on affirmative action

RSV injection headlines need to be accurate for good uptake

focus

Medicare innovation center doesn’t save money, experts say

Experts study whether long Covid risk adds up with each reinfection

CommonSpirit Health keeps growing, even as it loses money

Medicare innovation center doesn’t save money, experts say

Experts study whether long Covid risk adds up with each reinfection

CDC picks Alphabet's Verily for wasterwater surveillance contract

leisure time

hotspot

knowledge

hotspot